Pharmacists

Three parts of your work where AI is already doing real lifting, and what stays yours.

• Mortar1820–1900

  Mortar, pestle, and US Pharmacopeia: the compounding era

  For more than a century of the modern American pharmacy, the pharmacist's primary tool was the mortar and pestle. A prescription from a physician was a formula: "take these crude ingredients, combine them in these proportions, and prepare them in this form." The pharmacist was part chemist, part craftsperson: grinding, dissolving, filtering, and shaping medications from raw botanical and chemical materials. The 1820 US Pharmacopeia gave this craft its scientific foundation, establishing standard formulations for hundreds of drugs and the analytical tests required to verify their quality. The APhA (1852) added professional organization; state licensing laws (beginning with Louisiana, 1869) added legal exclusivity. By 1890 the pharmacist was a licensed professional with a defined body of knowledge, a regulated scope of practice, and a set of tools (the mortar, the prescription balance, the dispensing vials) that would not fundamentally change until the 1950s.

  Effect on the work

  Compounding was skilled labor that resisted mechanization. A pharmacist who could prepare a stable suppository or an accurate ophthalmic solution was doing work that required years of training and could not easily be delegated. This skill premium supported wages throughout the compounding era.

• FDCA1938–1960

  FDCA (1938) + commercial pharmaceutical manufacturing: the dispensing transition

  The Federal Food, Drug, and Cosmetic Act of 1938 gave the FDA authority to require safety demonstrations before drug marketing, accelerating the pharmaceutical industry's shift to large-scale commercial production. The 1943 mass production of penicillin (and the subsequent wave of antibiotics, antihypertensives, and other synthetic drugs) made it economically irrational for individual pharmacists to compound what a factory in New Jersey could produce for pennies. By the early 1950s, as the Wikipedia article on compounding notes, "the majority of dispensed drugs came directly from the large pharmaceutical companies." Pharmacists went from mixing drugs to counting and dispensing pre-packaged tablets. The 1951 Durham-Humphrey Amendment (co-sponsored by Senator Hubert Humphrey and Representative Carl Durham, both pharmacists) formally divided drugs into prescription and OTC categories, requiring licensed dispensing for the former and establishing the refill-authorization system that became a pharmacist's daily operational framework.

  Effect on the work

  The transition from compounding to dispensing deskilled the manual preparation work but created a new clinical role: the pharmacist as drug-interaction expert, patient counselor, and licensed gatekeeper to controlled medications. Prescription volume grew dramatically as new drug categories emerged; employment grew with it.

• Medicare / Medicaid1965–1995

  Medicare / Medicaid (1965) + retail pharmacy computer systems: the volume era

  Medicare and Medicaid (signed July 30, 1965) were the largest single drivers of retail prescription volume in US history. The elderly and low-income populations who had previously ration-filled prescriptions due to cost now had coverage; prescription volume at retail pharmacies roughly doubled over the following decade. Simultaneously, the retail pharmacy chains (Walgreens, Rite Aid [founded 1962], CVS [founded 1963 as Consumer Value Stores]) were expanding aggressively into the suburban shopping-center model, creating the high-volume, 200-prescription-per-day pharmacy that would define the profession for the next decades. Early prescription dispensing computer systems (Rx-30, QS/1, and others entering the market in the 1980s) automated label printing, drug-interaction checking, and insurance billing, allowing pharmacists to process higher volumes without proportional headcount increases.

  Effect on the work

  The 1965-1995 era was the golden age of retail pharmacy employment growth: prescription volume grew between 1970 and 1994 as baby boomers aged and new chronic-disease drug categories expanded. Pharmacist wages rose steadily; the profession attracted applicants with competitive undergraduate records who might otherwise have pursued medicine.

• ScriptPro / Parata robotic dispensing +…1994–2015

  ScriptPro / Parata robotic dispensing + automatic dispensing cabinets

  ScriptPro LLC was founded in 1994 and commercialized the first pharmacy robotic dispensing system for high-volume retail environments. The ScriptPro SP 200 (and successors) could count, cap, and label over 200 prescription fills per hour using a carousel of drug canisters and a robotic arm, matching the throughput of a skilled pharmacy technician without breaks, errors, or overtime. Parata Systems developed competing automated dispensing technology for both retail and institutional pharmacy settings. By the 2000s, every major chain pharmacy (CVS, Walgreens, Rite Aid) was deploying robotic dispensing in high-volume locations, primarily to reduce technician labor costs rather than pharmacist hours directly. The clinical argument used to justify keeping pharmacists while automating counting: the pharmacist's value was in verification, patient counseling, and drug-interaction review, not pill counting. For hospital pharmacy, Pyxis automated dispensing cabinets (introduced in the 1990s) moved medication storage to the point of care on nursing units, allowing pharmacists to spend more time on clinical review rather than cart-filling.

  Effect on the work

  Robotic dispensing did not reduce pharmacist headcount in the short term: prescription volumes were growing fast enough to absorb the productivity gain. The long-term effect was to concentrate retail pharmacy into higher-volume locations (which could justify robotic investment), accelerating chain consolidation and the closure of independent pharmacies that could not compete on price.

• Medicare Part D2003–2020

  Medicare Part D (2006) + Medication Therapy Management: the clinical-services era

  The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 created Medicare Part D: the largest expansion of prescription drug benefits in US history, effective January 2006. Part D did two things for pharmacists: it drove an enormous increase in covered prescription fills for Medicare beneficiaries (adding tens of millions of new covered patients over time), and it mandated that Part D plans include Medication Therapy Management (MTM) programs. MTM authorized pharmacists to conduct comprehensive medication reviews, identify drug-therapy problems, and bill Medicare directly for the service: the first time pharmacists had a widely reimbursed clinical service distinct from dispensing. By 2014, CMS required all Part D plans to include MTM programs, and enrolled patients with multiple chronic conditions (a few conditions and several medications) were eligible for annual comprehensive reviews. MTM transformed the policy argument for clinical pharmacy: rather than justifying pharmacist employment by prescription volume alone, health systems and insurers now had a billing framework for pharmacist cognitive services.

  Effect on the work

  MTM created new employment categories (ambulatory care pharmacists, integrated health-system clinical pharmacists, Medicare Part D MTM specialists) that partially offset retail employment pressures from automation and chain closures. The clinical track offered better work conditions and grew through the 2010s, while retail pharmacy employment stagnated.

• COVID-19 vaccination programs2020–2022

  COVID-19 vaccination programs: pharmacists as mass immunizers

  The COVID-19 pandemic activated a long-latent legal authority: since 2006, most states had granted pharmacists the right to administer vaccinations, but retail vaccination had been primarily seasonal flu shots. The federal government's emergency authorization under the PREP Act (Public Readiness and Emergency Preparedness Act) allowed pharmacists to administer COVID-19 vaccines to patients of all ages, transforming retail pharmacies into primary vaccine administration sites. At peak vaccination demand (spring 2021), pharmacies were administering millions of COVID doses per week: CVS alone administered over 30 million COVID vaccines by mid-2021. For pharmacists, this was a moment of extraordinary professional visibility: they were the accessible, no-appointment-needed front line of the largest mass vaccination campaign in American history. The immunization authority demonstrated that pharmacist scope could expand rapidly when political will aligned with public health need.

  Effect on the work

  Vaccination-driven demand created temporary staffing pressure and reinforced the clinical-pharmacist narrative: that pharmacist value is highest in direct patient care, not behind a counting machine. The authority was expected to persist post-pandemic, adding a durable immunization dimension to retail pharmacist scope.

• Chain implosion + central-fill automati…2021–present

  Chain implosion + central-fill automation: the restructuring era

  Three simultaneous forces reshaped retail pharmacy after 2021. First, the mass closure wave: CVS announced hundreds of US store closures in November 2021 (approximately 10% of its footprint), Walgreens announced up to 2,150 closures (25% of stores) in June 2024, and Rite Aid (which had operated 5,059 stores at its 2008 peak) filed for Chapter 11 bankruptcy in October 2023 and liquidated completely by October 2025. Second, central-fill automation: all three chains had been shifting high-volume chronic-medication fills to central automated facilities (essentially warehouses of robotic dispensing equipment), routing routine refills away from retail pharmacies and leaving retail locations to handle acute prescriptions and clinical services. Third, mail-order and PBM-owned pharmacies (CVS Caremark, Express Scripts) continued capturing the chronic-refill market from retail. The combined effect: fewer retail pharmacy locations, each serving higher patient volumes, with more automation and fewer staff per prescription filled.

  Effect on the work

  The chain closures created a paradox: retail pharmacist employment pressure increased even as BLS projected overall growth, because the new jobs (health-system clinical pharmacy, MTM specialists, ambulatory care) required different credentials and were located in different settings than the retail jobs being eliminated. Pharmacists in rural areas and communities that lost their only drugstore faced the hardest transitions.